Lung cell discovery opens new route for cystic fibrosis treatment fiercebiotech.com/research/lung-…

Congratulations Steve and Susan for being part of this discovery. A previously unknown airway cell type may be a key to efforts to cure cystic fibrosis hms.harvard.edu/news/new-lung-…

An excellent piece on modern #cysticfibrosis research and treatment at UAB. We're very proud of the work done by the entire UAB CF Center team! bit.ly/2RO8Sbv

We held our 2018 Scientific Symposium “Therapeutic Development for Nonsense Mutations: The Final Frontier of CF” on September 25 at The Wistar Institute in Philadelphia and we’re super excited to provide you with a recap in our latest blog! bit.ly/2zW0pfz #cureCF #beatCF #EE

UAB presence at "Therapeutic Development for Nonsense Mutations: The Final Frontier of CF" EE symposium held at Wistar institute, Philadelphia.

Where to go for rare disease diagnoses after exome sequencing fails? Excellent review of the options by @LaureFresard and @sbmontgom: m.molecularcasestudies.cshlp.org/content/4/6/a0…

UAB CF center recruiting patients with two copies of W1282X mutations to study the beneficial effect of Symdeko "Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations" Link: clinicaltrials.gov/ct2/results?co…

#3. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy #Science tinyurl.com/y9cxbq43 There's still concerns over off-target effects, Cas9 T-cell immunoreactivity, & the long-term effects, but the field will likely move forward in 2019.

Honored to be featured in a beautifully written STAT article this morning showcasing the 10% of the CF community without life-saving therapeutics. Thank you Andrew Joseph & everyone who took part! READ MORE> bit.ly/2GaEFS7 #cureCF #cfaware #patientadvocacy

Exciting news to CF patients..:)

Mutation in CFTR Gene Affects the Body’s Inner Clock, Mouse Study Suggests buff.ly/2VVit6G

Vertex announced today that it will seek U.S. FDA approval for its CFTR modulator VX-445 combined with tezacaftor/ivacaftor in the third quarter. If approved, the drug could eventually benefit more than 90% of people with #cysticfibrosis. #CFresearch on.cff.org/30Wrtan

Eloxx Pharmaceuticals Will Launch Phase 2 ELX-02 Trial for CF Patients Carrying G542X Mutation cysticfibrosisnewstoday.com/2019/08/06/elo…

UAB CF center recruiting patients with CF nonsense mutations to study the beneficial effect of Symdeko "Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations" Link:clinicaltrials.gov/ct2/show/NCT03…

The Foundation has awarded up to $1.61 million to Eloxx Pharmaceuticals Inc. to conduct an early Phase 2 clinical trial of an investigational drug that could potentially treat people with #cysticfibrosis who have a nonsense mutation. #CFresearch on.cff.org/2l1JJ29

Images of the Year in Pulmonary Disease: Ferret Lung COPD imaging #COPD #ferretlung #images

Vertex Announces Positive Phase 3 data for one of our #cysticfibrosis medicines. Learn more: bit.ly/2ZHwFQW

👨‍⚕️ Researchers from KU Leuven studied cystic fibrosis transmembrane conductance regulator (CFTR) function in #organoids of subjects with common and rare CFTR mutations. bit.ly/2L1AoVc